The group's revenue climbed 15.7%, beating expectations. The French pharmaceutical giant Sanofi has revised its outlook for 2022 upwards, after a sharp increase in sales in the second quarter, its flagship drug Dupixent continuing to garner sales in various indications. The group's revenues rose by 15.7% (+8.1% at constant exchange rates) to reach 10.1 billion euros, a figure higher than expected by a consensus of analysts polled by Bloomberg. Net prof
The French pharmaceutical giant Sanofi has revised its outlook for 2022 upwards, after a sharp increase in sales in the second quarter, its flagship drug Dupixent continuing to garner sales in various indications.
The group's revenues rose by 15.7% (+8.1% at constant exchange rates) to reach 10.1 billion euros, a figure higher than expected by a consensus of analysts polled by Bloomberg.
Net profit is down slightly to 1.17 billion euros (-1.9%).